C31G oral rinse

Drug Profile

C31G oral rinse

Alternative Names: 0.5% C31G oral rinse; 0.5% glyminox; Oramed

Latest Information Update: 07 Aug 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biosyn
  • Class
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Candidiasis

Most Recent Events

  • 31 Dec 2006 Discontinued - Phase-I/II for Candidiasis in USA (PO)
  • 15 Dec 2004 Biosyn has been acquired by Cellegy Pharmaceuticals
  • 12 Oct 2004 Cellegy Pharmaceuticals has entered into a definitive agreement to acquire Biosyn
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top